Media Coverage

Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others. Take a look at the latest Evaluate and Vantage coverage.

If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.

Latest Media Coverage

Browse the archive

The Pharma Letter

Look back at pharma news in the week to August 30

In paying $25 million up front to license Ionis Pharmaceuticals’ chronic hepatitis B antisense therapies GlaxoSmithKline looks to have cut a better deal than Johnson…

The Pharma Letter

Look back at pharma news in the week to August 24

Coming in the wake of news of a substantial delay to its gene therapy project, SRP-9001, which was then hit by a safety scare a couple of days later, it is little wonder…

The Pharma Letter

Look back at pharma news in the week to August 16

In its last two acquisition forays Jazz Pharmaceuticals has bought oncology companies, but last week’s purchase of Cavion marks a return to its central nervous system…

Vantage logo
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.